Related Experiment Videos
[Experience with the use of 9,3"-diacetylmidecamycin dry syrup in pediatrics]
Insights
9,3"-diacetylmidecamycin (MOM) dry syrup shows promising results in treating pediatric pneumonia. This macrolide antibiotic demonstrated good to excellent therapeutic effects with no significant side effects, indicating its potential for pediatric use.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and pharmacokinetics
- Respiratory medicine
Background:
- Macrolide antibiotics are crucial in treating pediatric respiratory infections.
- Evaluating new antibiotic formulations for improved pediatric compliance and efficacy is essential.
Observation:
- A single 10 mg/kg dose of 9,3"-diacetylmidecamycin (MOM) dry syrup in a child showed a peak blood concentration of 0.88 µg/mL at 1 hour, falling below detectable levels by 4 hours.
- Urinary excretion of MOM was 6.7% within 6 hours post-administration.
- Oral administration of MOM dry syrup for 7 days to 4 pediatric pneumonia patients (including 2 with mycoplasmal pneumonia) at 15.2–20.5 mg/kg/day resulted in excellent outcomes in 2 cases and good outcomes in 2 cases.
Findings:
- MOM dry syrup demonstrated high efficacy in treating pediatric pneumonia, with all patients showing good to excellent therapeutic results.
- The antibiotic was well-tolerated, with no observed side effects like exanthema.
- One patient experienced mild, transient elevations in total bilirubin, GOT, and GTP levels.
- Patients found the MOM dry syrup palatable and easy to ingest, suggesting good compliance.
Implications:
- 9,3"-diacetylmidecamycin (MOM) dry syrup presents a viable and palatable treatment option for pediatric pneumonia.
- Further pharmacokinetic studies are warranted to fully understand MOM's absorption, distribution, metabolism, and excretion in children.
- The favorable safety and efficacy profile supports the potential of MOM dry syrup in pediatric clinical practice.
Abstract:
Some studies were carried out on the use of 9,3"-diacetylmidecamycin (MOM) dry syrup, a new macrolide antibiotic preparation, in the treatment of children. The results are summarized below. 1) A single oral dose of 10 mg/kg of the MOM dry syrup was administered to 1 child at 2 hours after a meal. The peak concentration of the antibiotic in the blood was 0.88 micrograms/ml and occurred at 1 hour after administration. At 2 hours the concentration had fallen to 0.59 microgram/ml, and after 4 hours the blood level was already below the minimum detectable concentration (0.5 microgram/ml). During the first 6 hours after the administration, 6.7% of the MOM was recovered in the urine. 2) The MOM dry syrup was orally administered to 4 pneumonia patients (including 2 cases of mycoplasmal pneumonia) for 7 days at a daily dosage of 15.2--20.5 mg/kg (divided into 3 equal doses). The therapeutic results were excellent in 2 cases, good in 2 cases and poor in none. 3) No side effects such as exanthema were observed to occur. In 1 case only, there was a mild and temporary elevation in the laboratory test values for total bilirubin, GOT and GTP. 4) All 4 of the pneumonia patients found the MOM dry syrup to be easy to ingest. The taste and odor of this antibiotic preparation were judged to be sufficiently palatable to permit convenient use in the treatment of children.